Ms. Fang Min (房敏) joined our Group as a senior director to set up our clinical medicine department on December 24, 2017 and served as a vice president of clinical medicine from April 2021 to February 2023. Since March 2023, she has been serving as the deputy general manager of our Company. She is mainly responsible for the management of clinical strategy and operations of our Group.

Ms. Fang has extensive experience in clinical drug R&D, clinical trials and related management. Prior to joining our Group, she once worked at Schering-Plough China Co., Ltd.(先灵葆雅(中国)有限公司), a subsidiary of Schering-Plough Corporation (currently known as Merck & Co., Inc.), a global pharmaceutical company engaged in the production, sales and wholesale of anti-allergy and skin care drugs whose shares are listed on NASDAQ (stock code:MRK), and served as a senior clinical research manager at GlaxoSmithKline (China) R&D Company Limited (葛兰素史克(上海)医药研发有限公司), a wholly owned subsidiary of GSK plc, a company engaged in the R&D and production of prescription drugs, vaccines and healthcare products whose shares are listed on the London Stock Exchange (stock code: GSK).From January 2015 to September 2015, Ms. Fang served as the director of global clinical operations and project management at BeiGene (Beijing) Co., Ltd. (百济神州(北京)生物科技有限公司), a subsidiary of BeiGene, Ltd. (百济神州有限公司), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines whose shares are listed on the Stock Exchange (stock code: 6160). From October 2015 to April 2017, Ms. Fang worked at WuXi AppTec (Shanghai) Co., Ltd. (上海药明康德新药开发有限公司), a company mainly engaged in the R&D of new drugs and drug intermediates and is a wholly owned subsidiary of WuXi AppTec Co., Ltd. (无锡药明康德新药开发股份有限公司) whose shares are listed on both the Stock Exchange (stock code: 02359) and the Shanghai Stock Exchange (stock code: 603259). From April 2017 to October 2017, Ms. Fang worked at Centaurus BioPharma Co., Ltd. (北京赛林泰医药技术有限公司), a company primarily engaged in oncology and diabetes drug development.

Ms. Fang graduated from Xi’an Jiaotong University (西安交通大学) in the PRC in July 2000 with a bachelor’s degree in clinical medicine. She further obtained a master’s degree in educational and training systems design from University of Twente in the Netherlands in August 2003.